BCX-1777 in Treating Patients With Refractory Cutaneous T-Cell Lymphoma
Status:
Completed
Trial end date:
2008-01-01
Target enrollment:
Participant gender:
Summary
RATIONALE: BCX-1777 may stop the growth of cancer cells by blocking the enzymes necessary for
cancer cell growth.
PURPOSE: Phase I/II trial to study the effectiveness BCX-1777 in treating patients who have
refractory cutaneous T-cell lymphoma.